Precision Therapy for Invasive Fungal Diseases

Area of Science:

• Medical Mycology
• Pharmacology
• Infectious Diseases

Background:

• Invasive fungal infections (IFIs) are a significant cause of mortality in immunocompromised individuals.
• Invasive aspergillosis affects millions annually, necessitating effective antifungal treatments.
• Current pharmacokinetic (PK) and pharmacodynamic (PD) studies inform population-based antifungal regimens.

Purpose of the Study:

• To critically evaluate current antifungal therapy approaches for invasive fungal infections.
• To explore future research directions for optimizing antifungal effectiveness at the individual patient level.
• To address the limitations of 'one-size-fits-all' antifungal treatment strategies.

Main Methods:

• Review of existing literature on antifungal drug pharmacokinetics and pharmacodynamics.
• Analysis of current therapeutic drug monitoring and in vitro susceptibility breakpoint strategies.
• Discussion of research gaps in personalized antifungal medicine.

Main Results:

• Population-based PK/PD strategies ensure safe and effective antifungal therapy for the majority.
• These generalized approaches do not account for individual patient variability in drug response.
• The current paradigm falls short of the ideal clinician-patient relationship, which requires individualized treatment assessment.

Conclusions:

• A shift from population-based to individualized antifungal therapy is crucial for maximizing treatment benefits.
• Further research is needed to develop personalized strategies for invasive fungal infections.
• Optimizing antifungal therapy at the individual level will improve outcomes for at-risk patients.